/ALNA

ALNA Stock - Allena Pharmaceuticals, Inc.

Q: What is the analyst price target for ALNA?

Analyst price target information is not currently available for ALNA.

Q: What is ALNA's market cap?

Market capitalization information is not currently available for ALNA.

Healthcare|Biotechnology|NASDAQ

$0.07+3.16%

+$0.00 (+3.16%) • Sep 7

GoAI Score

Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.

HOLD

Medium Confidence

Momentum

Momentum Score

Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.

Sentiment

Sentiment Score

Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).

Risk Score

Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.

Price Target

Average analyst price target from the last quarter. Shows expected upside/downside from current price.

+10.0%upside

Target: $0.08

AI Analysis PreviewPremium

Real-time AI-powered market analysis

Precise entry/exit price targets

Risk assessment & position sizing

Unlock GoAI Insights for ALNA

Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.

Buy/Sell Signals

94% win rate on Alpha signals

Deep Analysis

Institutional-grade thesis

Real-Time Alerts

SMS & push notifications

Risk Scoring

Multi-factor analysis

Free 14-day trial • No credit card required

Financial Statements

Revenue & Profitability Trend

FY2017

FY2018

FY2019

FY2020

FY2021

← Swipe to see more →

Revenue

Net Income (Profit)

Net Loss

Key Metrics

Market CapN/A

P/E RatioN/A

Beta1.15

52W High$N/A

52W Low$N/A

Avg VolumeN/A

Income Statement (Fiscal Year)

Metric	FY2021	FY2020	FY2019	FY2018	FY2017
Revenue	N/A	N/A	N/A	N/A	N/A
Gross Profit	N/A	N/A	N/A	N/A	N/A
Gross Margin	N/A	N/A	N/A	N/A	N/A
Operating Income	$-32,335,000	$-31,986,000	$-46,920,000	$-35,593,000	$-20,950,000
Net Income	$-33,355,000	$-32,845,000	$-47,339,000	$-35,648,000	$-21,650,000
Net Margin	N/A	N/A	N/A	N/A	N/A
EPS	$-1.03	$-1.01	$-2.13	$-1.72	$-4.79

Company Overview

Allena Pharmaceuticals, Inc., a biopharmaceutical company, discovers, develops, and commercializes oral enzyme therapeutics to treat patients with rare and severe metabolic, and kidney disorders in the United States. Its lead product candidate is ALLN-346, a novel and urate degrading enzyme for patients with hyperuricemia and gout in the setting of advanced chronic kidney disease. The company was incorporated in 2011 and is headquartered in Newton, Massachusetts.

Visit Website

Earnings History & Surprises

ALNA

Beat Rate

55%

Last 20 quarters

Avg Surprise

-28.1%

EPS vs Estimate

Beats / Misses

11/8

1 met exactly

Latest EPS

$-0.08

Q3 2022

EPS Surprise History

Q4 20

-4.8%

$-0.22vs$-0.21

Q1 21

-26.3%

$-0.24vs$-0.19

Q2 21

+8.7%

$-0.21vs$-0.23

Q3 21

-14.3%

$-0.24vs$-0.21

Q4 21

+5.6%

$-0.17vs$-0.18

Q1 22

+31.3%

$-0.11vs$-0.16

Q2 22

+7.1%

$-0.13vs$-0.14

Q3 22

-14.3%

$-0.08vs$-0.07

Beat Estimate

Missed Estimate

Quarterly EPS Details

Period	Report Date	Estimated EPS	Actual EPS	Surprise	Result
Q3 2022	Aug 15, 2022	$-0.07	$-0.08	-14.3%	✗ MISS
Q2 2022	May 16, 2022	$-0.14	$-0.13	+7.1%	✓ BEAT
Q1 2022	Mar 31, 2022	$-0.16	$-0.11	+31.3%	✓ BEAT
Q4 2021	Nov 10, 2021	$-0.18	$-0.17	+5.6%	✓ BEAT
Q3 2021	Aug 10, 2021	$-0.21	$-0.24	-14.3%	✗ MISS
Q2 2021	May 11, 2021	$-0.23	$-0.21	+8.7%	✓ BEAT
Q1 2021	Mar 9, 2021	$-0.19	$-0.24	-26.3%	✗ MISS
Q4 2020	Nov 9, 2020	$-0.21	$-0.22	-4.8%	✗ MISS
Q3 2020	Aug 5, 2020	$-0.27	$-0.26	+3.7%	✓ BEAT
Q2 2020	May 13, 2020	$-0.44	$-0.31	+29.5%	✓ BEAT
Q1 2020	Mar 16, 2020	$-0.53	$-0.47	+11.3%	✓ BEAT
Q4 2019	Nov 13, 2019	$-0.49	$-0.57	-16.3%	✗ MISS
Q3 2019	Aug 7, 2019	$-0.54	$-0.54	0.0%	= MET
Q2 2019	May 8, 2019	$-0.49	$-0.55	-12.2%	✗ MISS
Q1 2019	Mar 7, 2019	$-0.50	$-0.46	+8.0%	✓ BEAT
Q4 2018	Nov 7, 2018	$-0.47	$-0.46	+2.1%	✓ BEAT
Q3 2018	Aug 7, 2018	$-0.40	$-0.42	-5.0%	✗ MISS
Q2 2018	May 8, 2018	$-0.42	$-0.38	+9.5%	✓ BEAT
Q1 2018	Mar 27, 2018	$-0.55	$-0.48	+12.7%	✓ BEAT
Q4 2017	Dec 14, 2017	$-0.50	$-3.49	-598.0%	✗ MISS

Frequently Asked Questions about ALNA

What is ALNA's current stock price?

Allena Pharmaceuticals, Inc. (ALNA) is currently trading at $0.07 per share. The stock has moved +3.16% today.

What is the analyst price target for ALNA?

No analyst price targets are currently available for this stock.

What sector is Allena Pharmaceuticals, Inc. in?

Allena Pharmaceuticals, Inc. operates in the Healthcare sector, specifically within the Biotechnology industry. The company is traded on the NASDAQ exchange.

What is ALNA's market cap?

Allena Pharmaceuticals, Inc. has a market capitalization of N/A, making it a small-cap company.

Does ALNA pay dividends?

No, Allena Pharmaceuticals, Inc. does not currently pay a dividend to shareholders.